BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp decreased its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 17.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,229 shares of the conglomerate’s stock after selling 23,523 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Danaher were worth $30,924,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC boosted its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. TD Asset Management Inc grew its stake in shares of Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after purchasing an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the last quarter. International Assets Investment Management LLC raised its stake in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after buying an additional 428,897 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its holdings in Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after buying an additional 397,671 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Danaher Stock Performance
NYSE:DHR opened at $239.84 on Friday. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The firm has a market cap of $173.23 billion, a price-to-earnings ratio of 45.77, a price-to-earnings-growth ratio of 4.39 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s fifty day moving average price is $254.59 and its 200 day moving average price is $259.44.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.
Wall Street Analysts Forecast Growth
DHR has been the topic of a number of recent analyst reports. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Raymond James reduced their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Stephens restated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $287.16.
Check Out Our Latest Research Report on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 11/25 – 11/29
- The Significance of Brokerage Rankings in Stock Selection
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.